What's Happening?
The U.S. Food and Drug Administration (FDA) has granted priority review to two supplemental Biologics License Applications (sBLA) for Keytruda (pembrolizumab) and Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with
Padcev (enfortumab vedotin-ejfv). These applications are for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The applications are supported by the Phase 3 KEYNOTE-B15 trial results, which demonstrated significant improvements in event-free survival and overall survival. If approved, these regimens would be the first perioperative treatments for MIBC patients regardless of cisplatin eligibility, potentially setting new standards of care. The FDA has set a target action date of August 17, 2026.
Why It's Important?
This development is significant as it could lead to the first approved perioperative treatments for muscle-invasive bladder cancer, a condition with limited treatment options. The approval of these regimens could improve survival rates and outcomes for patients who are eligible for cisplatin-based chemotherapy. The combination of Keytruda and Padcev has already shown benefits in other forms of bladder cancer, and this new indication could further expand its use, potentially reshaping treatment approaches and offering new hope to patients facing this aggressive disease.
What's Next?
The FDA's decision on these applications is expected by August 17, 2026. If approved, the new regimens could be rapidly integrated into clinical practice, offering a new standard of care for MIBC patients. Merck, the company behind Keytruda, plans to share the trial results with regulatory authorities worldwide, which could lead to further approvals in other regions. The ongoing research and additional Phase 3 studies will continue to evaluate the efficacy of Keytruda in various stages of bladder cancer.
